Certainly Health vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
SF YC S23 doctor booking with upfront cost guarantees via ML price prediction; $2.3M Pacific 8/YC seed Dec 2023 solving 57% surprise bills and 38% delayed care competing with Zocdoc for healthcare price transparency booking.
About
Certainly Health is a San Francisco-based healthcare price transparency marketplace — backed by Y Combinator (S23) with $2.3 million in seed funding in December 2023 from Pacific 8 Ventures, Y Combinator, institutional investors, and angels — providing patients with a doctor booking platform that shows upfront out-of-pocket costs using machine learning to predict and guarantee healthcare spending before appointments, addressing the surprise medical bill crisis where 57% of Americans have received unexpected bills and 38% delay care due to cost uncertainty. Founded in 2023 by Daryl Sew and Kevin Chiu (Stanford graduate, former Uber engineer, and Uber Health founding member who grew that program to $100 million in 2 years), Certainly Health enables patients with insurance to book doctors while seeing the actual cost they will owe — not the sticker price.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.